219 related articles for article (PubMed ID: 33658300)
41. Leveraging Existing 16S rRNA Gene Surveys To Identify Reproducible Biomarkers in Individuals with Colorectal Tumors.
Sze MA; Schloss PD
mBio; 2018 Jun; 9(3):. PubMed ID: 29871916
[TBL] [Abstract][Full Text] [Related]
42. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
43. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
[TBL] [Abstract][Full Text] [Related]
44. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
45. Lack of follow-up colonoscopy after positive FOBT in an organized colorectal cancer screening program is associated with modifiable health care practices.
Correia A; Rabeneck L; Baxter NN; Paszat LF; Sutradhar R; Yun L; Tinmouth J
Prev Med; 2015 Jul; 76():115-22. PubMed ID: 25895843
[TBL] [Abstract][Full Text] [Related]
46. Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England.
Benton SC; Piggott C; Blyuss O; Li SJ; Mathews C; Carroll M; Duffy S
J Med Screen; 2021 Dec; 28(4):426-432. PubMed ID: 33983066
[TBL] [Abstract][Full Text] [Related]
47. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
Hundt S; Haug U; Brenner H
Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
[TBL] [Abstract][Full Text] [Related]
48. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
[No Abstract] [Full Text] [Related]
49. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
[TBL] [Abstract][Full Text] [Related]
50. The human gut microbiome as a screening tool for colorectal cancer.
Zackular JP; Rogers MA; Ruffin MT; Schloss PD
Cancer Prev Res (Phila); 2014 Nov; 7(11):1112-21. PubMed ID: 25104642
[TBL] [Abstract][Full Text] [Related]
51. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.
Shapiro JA; Bobo JK; Church TR; Rex DK; Chovnick G; Thompson TD; Zauber AG; Lieberman D; Levin TR; Joseph DA; Nadel MR
Am J Gastroenterol; 2017 Nov; 112(11):1728-1735. PubMed ID: 29016558
[TBL] [Abstract][Full Text] [Related]
52. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
53. Screen-detected and interval colorectal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective cohort.
Blanks R; Burón Pust A; Alison R; He E; Barnes I; Patnick J; Reeves GK; Floud S; Beral V; Green J
Int J Cancer; 2019 Aug; 145(3):728-734. PubMed ID: 30694563
[TBL] [Abstract][Full Text] [Related]
54. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
[TBL] [Abstract][Full Text] [Related]
56. Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis.
Beshara A; Ahoroni M; Comanester D; Vilkin A; Boltin D; Dotan I; Niv Y; Cohen AD; Levi Z
Int J Cancer; 2020 Mar; 146(6):1532-1540. PubMed ID: 31173655
[TBL] [Abstract][Full Text] [Related]
57. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
58. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
59. Colorectal cancer screening with faecal testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-analysis.
Jodal HC; Helsingen LM; Anderson JC; Lytvyn L; Vandvik PO; Emilsson L
BMJ Open; 2019 Oct; 9(10):e032773. PubMed ID: 31578199
[TBL] [Abstract][Full Text] [Related]
60. Role of double-contrast barium enema in colorectal cancer screening based on fecal occult blood.
Ciatto S; Castiglione G
Tumori; 2002; 88(2):95-8. PubMed ID: 12088265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
